The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Anton Hagenbeek Executive Steering Committee Member

Anton Hagenbeek Executive Steering Committee Member

Professor Anton Hagenbeek received his medical degree from the  Erasmus University, Rotterdam, NL. He was trained in experimental hematology at the Radiobiological Institute T.N.O., Rijswijk, NL, where he obtained his PhD in 1977. After training in clinical hematology in Rotterdam, NL, Prof. Hagenbeek obtained a fellowship in hematology at the  University of California, Los Angeles, US.

From 1982 to 1997, he worked as a staff member in the Department of Hematology at the  Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, NL, and was in charge of the autologous and allogeneic stem cell transplantation program between 1987 and 1994.

In 1993, Prof. Hagenbeek was appointed Professor of Clinical and Experimental Hemato-Oncology at the Erasmus University, Rotterdam, NL. His main research interests are in developmental therapeutics for leukemia, focusing on translational research from preclinical animal models and  in vitro studies to clinical application. From studies on measurable residual disease and experimental bone marrow transplantation (GvHD-GVL) in the early 1980s, he has now moved into gene therapy for hematological malignancies. His clinical research activities are mainly in the field of intergroup studies in Hodgkin and non-Hodgkin lymphomas.

He has co-authored more than 345 papers in peer-reviewed journals. In 1997, he was appointed Professor of Hematology at the  University Medical Centre Utrecht, Utrecht, NL. Since 2006, he has held a joint appointment as Professor of Hematology in the Department of Hematology at the  Academic Medical Centre, NL, and the  University of Amsterdam, NL.

Positions of responsibility/awards:

  • International consortium on developing new biological prognostic indices in lymphoma
  • International consortium on first-in-man phase I/II studies with new agents in lymphomas and chronic lymphocytic leukemia
| |